Correlation Between Pfizer and TOMARI
Specify exactly 2 symbols:
By analyzing existing cross correlation between Pfizer Inc and TOMARI 1512 28 SEP 26, you can compare the effects of market volatilities on Pfizer and TOMARI and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of TOMARI. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and TOMARI.
Diversification Opportunities for Pfizer and TOMARI
Excellent diversification
The 3 months correlation between Pfizer and TOMARI is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and TOMARI 1512 28 SEP 26 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on TOMARI 1512 28 and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with TOMARI. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of TOMARI 1512 28 has no effect on the direction of Pfizer i.e., Pfizer and TOMARI go up and down completely randomly.
Pair Corralation between Pfizer and TOMARI
Considering the 90-day investment horizon Pfizer Inc is expected to under-perform the TOMARI. In addition to that, Pfizer is 1.97 times more volatile than TOMARI 1512 28 SEP 26. It trades about -0.05 of its total potential returns per unit of risk. TOMARI 1512 28 SEP 26 is currently generating about 0.01 per unit of volatility. If you would invest 8,734 in TOMARI 1512 28 SEP 26 on August 31, 2024 and sell it today you would earn a total of 41.00 from holding TOMARI 1512 28 SEP 26 or generate 0.47% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 24.06% |
| Values | Daily Returns |
Pfizer Inc vs. TOMARI 1512 28 SEP 26
Performance |
| Timeline |
| Pfizer Inc |
| TOMARI 1512 28 |
Pfizer and TOMARI Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Pfizer and TOMARI
The main advantage of trading using opposite Pfizer and TOMARI positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, TOMARI can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TOMARI will offset losses from the drop in TOMARI's long position.| Pfizer vs. Johnson Johnson | Pfizer vs. RLJ Lodging Trust | Pfizer vs. Aquagold International | Pfizer vs. Stepstone Group |
| TOMARI vs. Xponential Fitness | TOMARI vs. Playtika Holding Corp | TOMARI vs. Skechers USA | TOMARI vs. Duluth Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Complementary Tools
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |